Document is current
Any future updates will be listed below
-
Authors
Rozeman, E. A.
Hoefsmit, E. P. https://orcid.org/0000-0002-3989-8175
Reijers, I. L. M.
Saw, R. P. M. https://orcid.org/0000-0002-3354-806X
Versluis, J. M.
Krijgsman, O.
Dimitriadis, P. https://orcid.org/0000-0002-3546-285X
Sikorska, K.
van de Wiel, B. A.
Eriksson, H.
Gonzalez, M.
Torres Acosta, A.
Grijpink-Ongering, L. G.
Shannon, K. https://orcid.org/0000-0001-8538-3132
Haanen, J. B. A. G. https://orcid.org/0000-0001-5884-7704
Stretch, J.
Ch’ng, S.
Nieweg, O. E. https://orcid.org/0000-0003-2997-6413
Mallo, H. A.
Adriaansz, S.
Kerkhoven, R. M.
Cornelissen, S.
Broeks, A.
Klop, W. M. C.
Zuur, C. L.
van Houdt, W. J.
Peeper, D. S. https://orcid.org/0000-0003-1293-3177
Spillane, A. J. https://orcid.org/0000-0002-9520-0181
van Akkooi, A. C. J.
Scolyer, R. A. https://orcid.org/0000-0002-8991-0013
Schumacher, T. N. M. https://orcid.org/0000-0003-0517-8804
Menzies, A. M.
Long, G. V.
Blank, C. U. https://orcid.org/0000-0002-7945-5846
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (CA209-701, CA209-278)
Funding was paid to the Netherlands Cancer Institute.
- License Information
-
More Information
Article History
Received: 3 August 2020
Accepted: 14 December 2020
First Online: 8 February 2021
Competing interests
: E.P.H., I.L.M.R., J.M.V., O.K., P.D., K. Sikorska, H.E., M.G., A.T.A., L.G.G.-O., K. Shannon, J.S., S. Ch’ng, O.E.N., H.A.M., S.A., R.M.K., S. Cornelissen, A.B., W.M.C.K., C.L.Z., W.J.v.H. and A.J.S. declared no competing interests. E.A.R. reports travel support from NanoString Technologies and MSD. R.P.M.S. has served on advisory boards for MSD Novartis Qbiotics and received honoraria from BMS. B.A.v.d.W. has served on advisory boards for BMS. J.B.A.G.H. has served on advisory boards for AIMM, Achilles, AZ/MEDimmune, Amgen, Bayer, BMS, GSK, Ipsen, Immunocore, MSD, Merck Sorono, Neon Therapeutics, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures and Vaximm, and reports research fees paid to the institute from BMS, MSD, Novartis and Neon Therapeutics. D.S.P. is cofounder, shareholder and advisor of Immagene BV. A.C.J.v.A. has served on advisory boards for Amgen, BMS, Novartis, MSD-Merck, Merck-Pfizer, Sanofi and 4SC, and reports research fees paid to the institute from Amgen, BMS and Merck-Pfizer. R.A.S. reports financial support from Qbiotics, Novartis, NeraCare, AMGEN, BMS, Myriad Genetics, GlaxoSmithKline and Merck Sharp & Dohme. T.N.M.S. has served on advisory boards for Adaptive Biotechnologies, AIMM Therapeutics, Allogene Therapeutics, Merus, BioNTech, Scenic Biotech; reports financial support from Merck KGaA; and is stockholder in AIMM Therapeutics, Allogene Therapeutics, Merus, Neogene Therapeutics, BioNTech and Scenic Biotech. A.M.M. has served on advisory boards for BMS, MSD, Novartis, Roche, Pierre Fabre and QBiotics. G.V.L. has served on advisory boards for Aduro, Amgen, BMS, Highlight Therapeutics S.L., Mass-Array, Merck, MSD, Novartis, OncoSec Medical, Pierre Fabre, Roche, Qbiotics and Sandoz. C.U.B. has served on advisory boards for BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre and Third Rock Ventures, for which the institute received funding; received research funding from BMS, Novartis and NanoString, all paid to the institute; stock ownership: Uniti Cars; and is cofounder of Immagene BV.
